In addition, it can be considered an important result that L1CAM, a new marker, is an indicator that can divide the prognosis from initial treatment for the p53wt/pMMR subgroup among advanced/recurrent endometrial cancers. This evidence concerns the gene L1CAM and endometrial cancer.